Alphagan Augndropar, lausn 2 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alphagan augndropar, lausn 2 mg/ml

abbvie a/s - brimonidinum tartrat - augndropar, lausn - 2 mg/ml

Botox Stungulyfsstofn, lausn 100 Allergan ein. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

botox stungulyfsstofn, lausn 100 allergan ein.

abbvie a/s - botulinum toxin type a - stungulyfsstofn, lausn - 100 allergan ein.

Vistabel Stungulyfsstofn, lausn 4 Allergan-einingar/0,1 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vistabel stungulyfsstofn, lausn 4 allergan-einingar/0,1 ml

abbvie a/s - botulinum toxin type a - stungulyfsstofn, lausn - 4 allergan-einingar/0,1 ml

Pulmozyme Lausn í eimgjafa 1 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmozyme lausn í eimgjafa 1 mg/ml

roche pharmaceuticals a/s - dornase alfa inn - lausn í eimgjafa - 1 mg/ml

Phelinun Evrópusambandið - íslenska - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - Æxlishemjandi lyf - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Pepaxti Evrópusambandið - íslenska - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - mergæxli - Æxlishemjandi lyf - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Bendamustine medac Stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bendamustine medac stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml

medac gesellschaft für klinische spezialpräparate gmbh - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml

Enzepi Evrópusambandið - íslenska - EMA (European Medicines Agency)

enzepi

allergan pharmaceuticals international ltd - brisi duft - skert nýrnastarfsemi í brjóstholi - meltingarfæri, þ.mt. ensím - brisi ensím skipti meðferð í útseytandi brisi lungnastarfsemi vegna þess að fá lungnasjúkdóm eða aðrar aðstæður (e. langvarandi brisbólga, eftir brisbólgu eða krabbamein í brisi). enzepi er ætlað í börn, börn, unglingum og fullorðnir.

Alkeran Filmuhúðuð tafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alkeran filmuhúðuð tafla 2 mg

aspen pharma trading limited - melphalanum inn - filmuhúðuð tafla - 2 mg

Ganfort Evrópusambandið - íslenska - EMA (European Medicines Agency)

ganfort

abbvie deutschland gmbh & co. kg - bimatoprost, notkunar í augu. - glaucoma, open-angle; ocular hypertension - augnlækningar - minnkun á augnþrýstingi (iop) hjá sjúklingum með gláku í augnlokum eða augnháþrýstingi sem eru ekki nægilega svör við staðbundnum beta-blokkum eða prostaglandín hliðstæðum.